Review of NICE Technology Appraisal Guidance No. 210; Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events

The Institute was proposing that the guidance should be transferred to the static guidance list.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

Consequently, TA210 will now be moved to the static guidance list. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

September 2013